What do women with PCOS report on Mounjaro or Ozempic, and how does it compare with the trials?

The short answer

Evidence tier: 2–3 for the PCOS-specific data (small randomised trials, meta-analyses rated low certainty, observational cohorts); 1 for regain after stopping (large RCTs, not PCOS-specific); 5 for what women report.

Women with PCOS describe the same things the trials show, plus some the trials never measured. Weight loss on Mounjaro (tirzepatide) and Ozempic or Wegovy (semaglutide) matches what the research describes. In one large UK cohort, women with PCOS lost about 19% of body weight at 10 months, similar to women without PCOS.

What the trials do not cover is much of what women ask about. Long plateaus, conceiving after stopping, regain, cost and "lean PCOS" come up constantly in community posts. PCOS trials are mostly small and short and many used older drugs such as liraglutide and exenatide.

The 2023 International PCOS Guideline says GLP-1s could be considered for weight management only. For fertility, it says these drugs belong in research settings for now.

The key points:

• Weight loss in PCOS is real, but a 2026 GRADE review rated the evidence low certainty and found only modest pooled effects, mostly from older drugs.
• Natural pregnancy rates rose in two meta-analyses of small trials. No trial has reported live births as a main outcome.
• We found only one published randomised tirzepatide trial in PCOS (60 women, 16 weeks). A larger placebo-controlled trial is recruiting.
• Regain after stopping is well documented in general obesity trials. No PCOS-specific withdrawal trial exists.
• Metformin is still the guideline's main metabolic drug for PCOS. Adding a GLP-1 to metformin gave more weight loss in trials.

For how these drugs act on insulin, androgens and ovulation, see our GLP-1s, PCOS and fertility explainer.

In 2026 PCOS was renamed polyendocrine metabolic ovarian syndrome (PMOS). We use "PCOS" because most women still search for it.

How did we read the community reports?

Evidence tier: 5 — community reports, used to find questions, not to answer them.

We grouped about 80 anonymised post titles from PCOS and GLP-1 communities into recurring themes, without quoting or identifying anyone: plateaus, trying to conceive, stopping and regain, side effects, period changes, lean PCOS, the pill, cost, and add-ons such as inositol. Each section below takes one theme.

Do women with PCOS lose as much weight as everyone else?

Evidence tier: 2–3 — meta-analyses of small RCTs (low certainty) plus a large observational cohort.

What women report: many describe steady loss. A recurring thread is the opposite: weeks or months with no change, and a worry that PCOS makes the drug work less well.

What the evidence shows:

• A 2026 GRADE review in the European Journal of Endocrinology (11 RCTs) found GLP-1 add-on therapy lowered BMI by about 1.4 kg/m² more than control, rated low certainty. The trials were mostly short and used older drugs.
• In a UK digital-clinic cohort of 54,114 women on tirzepatide, the 4,241 with self-reported PCOS lost about 19% of body weight at 10 months, not significantly different from women without PCOS. Only 40 women with PCOS reached the 10-month mark, PCOS was self-reported, and several authors work for the clinic.

So the best current data do not suggest PCOS blunts the effect. For context, in SURMOUNT-1, the main tirzepatide obesity trial, average loss at 72 weeks was 15% to 21% depending on dose. Trials report averages at fixed time points, so they do not show how often individuals hit long plateaus.

Can tirzepatide help you conceive with PCOS?

Evidence tier: 2–3 — two meta-analyses of small RCTs, one small tirzepatide RCT, one large observational study.

What women report: a recurring question is whether Mounjaro can help them get pregnant, and what to do when pregnancy happens sooner than expected.

What the evidence shows:

• A 2023 meta-analysis in BMC Endocrine Disorders (11 RCTs, 840 women) found GLP-1s raised the natural pregnancy rate (risk ratio 1.72). There was no significant effect on total or IVF pregnancy rates.
• A 2026 meta-analysis of three RCTs (252 women) comparing GLP-1-based treatment with metformin found higher natural pregnancy (moderate certainty). There was no clear effect on overall or IVF pregnancy.
• The only published randomised tirzepatide trial in PCOS gave 60 women metformin alone or metformin plus low-dose tirzepatide for 16 weeks. The tirzepatide group lost about 10 kg versus 2 kg and had more cycle recovery and more pregnancies. Pregnancies were counted only after the drug stopped and a contraception period ended.
• A 2026 target-trial emulation using a global health-records network compared about 48,000 women with PCOS who took GLP-1-type drugs before conception against matched women on metformin. Those on GLP-1-type drugs had a lower risk of adverse pregnancy outcomes. This is observational, and the authors stress it does not support use during pregnancy.

What the guideline says: the 2023 International PCOS Guideline recommends anti-obesity drugs for reproductive outcomes only in research settings. Letrozole remains the first-line drug for ovulation induction.

None of these studies measured live birth as the main outcome. A placebo-controlled tirzepatide trial in PCOS, run from Bonn with about 198 women, is recruiting. Its primary outcome is cycle regularity, not pregnancy; primary completion is listed for December 2028.

On timing, stopping before conception and what the labels say, see GLP-1s, contraception and pregnancy planning.

Can you take the pill with Mounjaro?

Evidence tier: 1 — FDA prescribing information.

What women report: questions about specific pills taken alongside Mounjaro come up often.

What the evidence shows: the US Zepbound label says tirzepatide may reduce how well oral hormonal contraceptives work because it slows stomach emptying. This effect is largest after the first dose. The label advises a non-oral method or a backup barrier method for set periods after starting and after each dose increase. The PCOS guideline also says effective contraception is needed whenever pregnancy is possible on a GLP-1.

The details are in our contraception and pregnancy planning guide. Your prescriber can say how this applies to your method.

Do periods change on GLP-1s?

Evidence tier: 2–5 — mixed meta-analysis findings; bleeding patterns largely undocumented.

What women report: some describe periods returning after years of irregular cycles. Others describe prolonged or unusual bleeding and ask if it is normal.

What the evidence shows: the 2023 meta-analysis found better menstrual regularity, but the results varied widely between studies. The 2026 GRADE review found the evidence insufficient to judge. No trial we found has described changes in bleeding pattern in detail.

Prolonged or heavy bleeding is not explained by the trial data and is worth raising with a clinician.

Does the weight come back after stopping?

Evidence tier: 1 — large randomised withdrawal trials in general obesity populations, not PCOS.

What women report: maintenance updates posted months after stopping are a recurring theme, alongside fear that food noise and weight will return.

What the evidence shows:

• In the STEP-1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year. Most heart and metabolic improvements went back toward baseline.
• In SURMOUNT-4, people who switched from tirzepatide to placebo after 36 weeks regained 14% of body weight over the next year. Those who continued lost a further 5.5%.

Neither trial was in PCOS. Because PCOS symptoms track insulin resistance and weight, it is reasonable to expect that some benefits fade if weight returns, but no trial has tested this directly. The guideline asks clinicians to discuss the possible need for long-term use before starting. More on this in stopping GLP-1s: rebound and regain.

Which side effects come up most?

Evidence tier: 1 — FDA labels; community reports tier 5.

What women report: nausea and diarrhoea early on, hair shedding, and less often gallstones and pancreatitis. Some describe trembling, cold sweats or tingling.

What the evidence shows: the labels list gastrointestinal effects as the most common, mostly during dose increases. The US labels carry a boxed warning on thyroid C-cell tumours seen in rodents, and warnings include gallbladder disease, pancreatitis and kidney injury from dehydration. Low blood sugar can occur; the risk is higher alongside insulin or sulfonylureas.

Shakiness and cold sweats have many possible causes. They call for a clinician's assessment, not self-diagnosis. For practical management see GLP-1 side effects and does Ozempic cause hair loss?.

What about lean PCOS and insulin resistance?

Evidence tier: 4–5 — no PCOS trials at normal BMI.

What women report: a recurring question is whether a low dose could treat insulin resistance in women with PCOS who are not overweight. Some ask about "microdosing".

What the evidence shows: the guideline's GLP-1 recommendation covers higher weight in adults with PCOS, following general obesity guidelines. We found no trials in lean PCOS and no trials of "microdosing". For women with a BMI under 25, the guideline says metformin may be considered, while noting the evidence is limited.

How does metformin compare?

Evidence tier: 1–2 — guideline plus head-to-head RCTs and meta-analyses.

Metformin remains the guideline's main metabolic drug: it should be considered for adults with PCOS and a BMI of 25 or more, for weight and metabolic outcomes. It is cheap, oral and well studied, though gastrointestinal side effects are common.

A 2023 meta-analysis of exenatide versus metformin (9 RCTs, 1,059 women) found higher pregnancy rates and larger falls in testosterone with exenatide; weight benefits were clearest when exenatide was added to metformin. The tirzepatide trial above used metformin as the comparator and found much greater weight loss with the combination.

On inositol, the guideline says metformin should be considered over inositol for central fat and hirsutism, and no inositol type or dose can be recommended.

What about cost and access?

Evidence tier: 5 for experiences; no cost-effectiveness studies exist.

What women report: insurance changes, prior-authorisation demands and price are a steady theme.

What the evidence shows: the 2026 GRADE review found no cost-effectiveness studies of GLP-1s in PCOS. No GLP-1 is approved for PCOS itself; in the US, EU and UK they are approved for weight management, so coverage usually depends on BMI and related conditions.

Questions to bring to your clinician

Evidence tier: — questions drawn from the evidence above; not a substitute for a consultation.

• Is my main goal weight, insulin resistance, cycle regularity or pregnancy, and does that change which treatment fits?
• How does a GLP-1 compare with metformin, or with combining the two, for me?
• What contraception works best with this drug, and what is the plan if I want to conceive?
• How long would I expect to stay on it, and what is the plan if I stop?
• Which side effects mean I should stop and call you?
• Should we track blood sugar, lipids, liver tests or body composition while I'm on it?
• If my BMI is under 25, what does the evidence support for my insulin resistance?

Limitations of the evidence

• Most PCOS trials are small and short, often under six months, and many used liraglutide or exenatide rather than semaglutide or tirzepatide.
• Live birth has not been a primary outcome in any PCOS GLP-1 trial; pregnancy rates come from secondary outcomes.
• Regain data come from general obesity trials, not women with PCOS.
• The large tirzepatide cohort relied on self-reported PCOS and was run by the clinic that prescribed the drug.
• Community reports are self-selected: people with problems or striking results post more often, and posts cannot show cause and effect.

The bottom line

What women with PCOS report on Mounjaro and Ozempic broadly matches the trials on weight. The gaps are elsewhere. Fertility benefits rest on small studies without live-birth data, regain evidence comes from non-PCOS trials, and there is nothing on lean PCOS or cost. The guideline says GLP-1s could be considered for higher weight in PCOS, alongside lifestyle support, and treats fertility use as research. Any decision to start, combine, stop or try to conceive belongs with your clinician.

Related on this site

• GLP-1s, PCOS and fertility: the basics
• GLP-1s, contraception and pregnancy planning (2026)
• Stopping GLP-1s: rebound and regain
• GLP-1 side effects and how to manage them
• Muscle loss on GLP-1s and how to prevent it
• Peptides for women: what's different and what's safe

References

• Teede HJ et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2023 — GLP-1s for higher weight; anti-obesity drugs for fertility only in research; metformin and inositol positions. PMID 37580314
• Forslund M et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol 2026 — 11 RCTs; BMI −1.38 kg/m², low certainty; insufficient evidence on cycles. PMID 41701618
• Zhou L et al. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome. BMC Endocr Disord 2023 — 11 RCTs; natural pregnancy RR 1.72. PMID 37940910
• Kar E et al. The effect of GLP-1 receptor agonists versus metformin on pregnancy rates in women with PCOS. Eur J Obstet Gynecol Reprod Biol 2026 — 3 RCTs; higher natural pregnancy, no clear IVF effect. PMID 42893679
• Yang Z et al. Short-term combined treatment with tirzepatide and metformin for overweight/obese Chinese women with PCOS. Diabetes Obes Metab 2026 — 60-woman RCT, 16 weeks. PMID 42236268
• Clift AK et al. Weight loss outcomes with tirzepatide in women with and without self-reported PCOS. J Endocr Soc 2026 — UK digital-clinic cohort; authors include clinic staff. PMID 42634795
• Henney AE et al. Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in PCOS. J Clin Endocrinol Metab 2026 — observational target-trial emulation versus metformin. PMID 42857939
• Hu Y et al. Comparison of exenatide alone or combined with metformin versus metformin in PCOS. BMC Endocr Disord 2023 — 9 RCTs, 1,059 women. PMID 37974132
• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022 — two-thirds of loss regained in a year. PMID 35441470
• Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction: the SURMOUNT-4 randomized clinical trial. JAMA 2024 — 14% regain on placebo. PMID 38078870
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022 — 15–21% mean weight loss at 72 weeks. PMID 35658024
• Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome. Lancet 2026 — global consensus on the PMOS name. PMID 42119588
• Eli Lilly. Zepbound (tirzepatide) prescribing information. DailyMed — oral contraceptive interaction; gallbladder and pancreatitis warnings. DailyMed
• University of Bonn. Tirzepatide on reproductive function and metabolic health in women with PCOS. ClinicalTrials.gov — recruiting, placebo-controlled. NCT07326111